- ISIN
- US87583X1090
- CUSIP
- 87583X109
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Sep 3, 2020
Highlights
- Market Cap
- $3.08B
- Enterprise Value
- $2.96B
- EPS (TTM)
- -$0.89
- Total Revenue (TTM)
- $56.99M
- Gross Profit (TTM)
- $55.33M
- EBITDA (TTM)
- -$111.92M
- Year Range
- $3.58 - $28.41
- Target Price
- $22.75
- ROA (TTM)
- -24.61%
- ROE (TTM)
- -27.39%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
TNGX Performance Chart
Tango Therapeutics, Inc. (TNGX) is up 142.3% since the beginning of the year. At $21 per share, TNGX is trading 24.4% below its 52-week high of $28. Investors who bought $1,000 worth of TNGX shares 5 years ago would now be looking at an investment worth $1,961.
Loading charts...
Returns By Period
Tango Therapeutics, Inc. (TNGX) has returned 142.33% so far this year and 562.65% over the past 12 months.
Tango Therapeutics, Inc.
- 1D
- -0.14%
- 1M
- -5.46%
- YTD
- 142.33%
- 6M
- 124.35%
- 1Y
- 562.65%
- 3Y*
- 88.81%
- 5Y*
- 14.42%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
TNGX Monthly Returns History
Based on dividend-adjusted daily data since Sep 3, 2020, TNGX's average daily return is +0.21%, while the average monthly return is +4.98%. At this rate, an investment would double in approximately 1.2 years.
Historically, 46% of months were positive and 54% were negative. The best month was Jun 2025 with a return of +130.6%, while the worst month was Sep 2024 at -34.9%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 7 months.
On a daily basis, TNGX closed higher 48% of trading days. The best single day was Aug 9, 2023 with a return of +103.9%, while the worst single day was Nov 6, 2024 at -37.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 31.04% | -4.05% | 87.79% | 3.35% | 1.67% | -2.32% | 142.33% | ||||||
| 2025 | -3.56% | -30.54% | -33.82% | 2.92% | 57.45% | 130.63% | 17.97% | 11.09% | 25.19% | -3.45% | 34.53% | -18.79% | 186.73% |
| 2024 | 18.69% | -5.28% | -28.66% | -3.02% | -10.13% | 23.99% | 14.80% | 20.10% | -34.91% | -29.42% | -27.51% | -21.57% | -68.79% |
| 2023 | -8.97% | -20.76% | -24.47% | -13.92% | -20.59% | 22.96% | 1.81% | 92.01% | 73.50% | -25.40% | -9.52% | 30.26% | 36.55% |
| 2022 | -22.03% | 7.39% | -17.25% | -2.90% | -9.10% | -32.29% | -9.71% | 0.24% | -11.71% | 122.10% | -6.59% | -3.46% | -33.73% |
| 2021 | -0.96% | 4.77% | -6.32% | 5.13% | -4.19% | 1.61% | -11.92% | 16.12% | 11.08% | -0.70% | -19.24% | 5.50% | -4.37% |
Benchmark Metrics
Tango Therapeutics, Inc. has an annualized alpha of 41.70%, beta of 1.16, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since September 04, 2020.
- This stock participated in 124.36% of S&P 500 Index downside but only 119.92% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 41.70%
- Beta
- 1.16
- R²
- 0.04
- Upside Capture
- 119.92%
- Downside Capture
- 124.36%
Return for Risk
Risk / Return Rank
TNGX ranks 98 for risk / return — in the top 98% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Tango Therapeutics, Inc. (TNGX) and compare them to S&P 500 Index.
| TNGX | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 6.52 | 2.24 | +4.28 |
Sortino ratioReturn per unit of downside risk | 5.05 | 3.07 | +1.98 |
Omega ratioGain probability vs. loss probability | 1.63 | 1.41 | +0.22 |
Calmar ratioReturn relative to maximum drawdown | 19.41 | 2.93 | +16.49 |
Martin ratioReturn relative to average drawdown | 51.43 | 13.52 | +37.91 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Tango Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Tango Therapeutics, Inc. was 93.64%, occurring on May 8, 2025. Recovery took 212 trading sessions.
The current Tango Therapeutics, Inc. drawdown is 22.69%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -93.64%May 2025 | 3y 7mo | 10mo 9d | 4y 5moSep 2021 - Mar 2026 |
2026 bear market2026 | -29.24%May 2026 | 1mo 5d | — | 1mo 13dApr 2026 - now |
2021 bear market2021 | -26.94%Aug 2021 | 5mo 20d | 26d | 6mo 16dFeb 2021 - Sep 2021 |
2021 correction2021 | -13.43%Feb 2021 | 28d | 17d | 1mo 15dJan 2021 - Feb 2021 |
2026 pullback2026 | -8.46%Apr 2026 | 1d | 7d | 8dApr 2026 - Apr 2026 |
Drawdown Indicators
| TNGX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -93.64% | -56.78% | -36.86% |
Max Drawdown (1Y)Largest decline over 1 year | -29.24% | -9.10% | -20.14% |
Max Drawdown (3Y)Largest decline over 3 years | -91.46% | -18.90% | -72.56% |
Max Drawdown (5Y)Largest decline over 5 years | -93.64% | -25.43% | -68.21% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -22.69% | -0.74% | -21.95% |
Average DrawdownAverage peak-to-trough decline | -48.20% | -10.72% | -37.48% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 11.02% | 1.97% | +9.05% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Tango Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Tango Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for TNGX relative to other companies in the Biotechnology industry. Currently, TNGX has a P/S ratio of 45.3. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for TNGX in comparison with other companies in the Biotechnology industry. Currently, TNGX has a P/B value of 7.9. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with TNGX
Add Tango Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with TNGX